The decision is supported by results from the Phase III ECLIPSE study, which assessed Aquipta versus placebo for migraine.
The ECLIPSE study showed Aquipta was more effective than placebo in achieving pain freedom at two hours after the first migraine attack treatment. Credit: Studio Romantic / Shutterstock.com.
AbbVie has received approval from the European Commission (EC) for Aquipta (atogepant), an oral calcitonin gene-related peptide (CGRP) receptor antagonist, for the acute treatment of migraine in adults, with or without aura.
This marks the second indication for Aquipta in the EU, where it is now approved both for acute attacks and as a once-daily preventive treatment for adults experiencing four or more migraine days each month. Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
